Feb 5, 2025
Dave Rosa is President and CEO of NeuroOne, a company focused on advancing neurotechnology by developing thin-film minimally invasive electrode technology that can perform diagnostic and therapeutic functions for neurological conditions. The company's OneRF ablation system allows doctors to identify and ablate problematic brain tissue in a single hospitalization. NeuroOne is expanding its technology beyond the brain to include the spine to treat pain and is addressing various neurological conditions through ablation, stimulation, and drug delivery.
Dave explains, "The OneRF ablation system is an electrode that looks very similar to the electrode that we got cleared shortly after our last discussion. So that was in October of 2022. But that device only had diagnostic capabilities. So what doctors would do is they would implant those electrodes, and they would leave the patient in the hospital for, say, up to a week on average."
"The goal was for the neurosurgeon and neurologist to be able to identify the parts of brain tissue that were triggering seizures or causing neurological issues. Then, after that procedure was done, the devices would be removed, and patients would go home. So that was kind of the old way of doing it."
"What we did was to have the ability to reduce the amount of hospitalizations a patient would have to experience. We did develop this electrode technology that looks very similar to the diagnostic one approved in April but with the capability of not just doing the diagnostics but also the ablation. So the difference here is that when the patient comes in for the diagnostic procedure after that concludes, the doctor will wheel them into the patient's room, not the operating room."
#NeuroOne #Neurosurgery #ElectrodeTechnology
